GamaSTAN S/D (Grifols Therapeutics, Inc., Research Triangle Park, North Carolina) is a sterile, preservative-free solution of immune globulin (IG) for intramuscular administration and is used for prophylaxis against disease caused by infection with hepatitis A, measles, varicella, and rubella viruses ([@R1]). GamaSTAN S/D is the only IG product approved by the Food and Drug Administration for hepatitis A virus (HAV) prophylaxis. In July 2017, GamaSTAN S/D prescribing information was updated with changes to the dosing instructions for hepatitis A preexposure and postexposure prophylaxis indications. These changes were made because of concerns about decreased HAV immunoglobulin G antibody (anti-HAV IgG) potency, likely resulting from decreasing prevalence of previous HAV infection among plasma donors, leading to declining anti-HAV antibody levels in donor plasma ([@R2]). No changes in dosing instructions were made for measles, varicella, or rubella preexposure or postexposure prophylaxis.

Following are the updated recommended doses of GamaSTAN S/D for hepatitis A preexposure and postexposure prophylaxis ([@R2]).

Preexposure Prophylaxis in Persons Who Plan to Travel in Areas with High or Intermediate Hepatitis A Endemicity
===============================================================================================================

The recommended dosages of GamaSTAN S/D, which vary according to planned duration of travel are as follows ([Table](#T1){ref-type="table"}):

###### Indications and updated dosage recommendations for GamaSTAN S/D human immune globulin for preexposure and postexposure prophylaxis against hepatitis A infection

  Indication                     Updated dosage recommendation
  ------------------------------ -----------------------------------
  **Preexposure prophylaxis**    
  Up to 1 month of travel        0.1 mL/kg
  Up to 2 months of travel       0.2 mL/kg
  2 months of travel or longer   0.2 mL/kg (repeat every 2 months)
  **Postexposure prophylaxis**   0.1 mL/kg

• Up to 1 month: 0.1 mL/kg

• Up to 2 months: 0.2 mL/kg

• 2 months or longer: repeat dose of 0.2 mL/kg every 2 months.

Postexposure Prophylaxis of Household and Institutional Hepatitis A Case Contacts
=================================================================================

The recommended dosage of GamaSTAN S/D is 0.1 mL/kg ([Table](#T1){ref-type="table"}). There is no maximum dosage of GamaSTAN S/D for hepatitis A prophylaxis ([@R1]).

The effect of IG preparations on the response to certain live-virus vaccines is unknown, but antibodies in GamaSTAN S/D might interfere with live-virus vaccines such as measles, mumps, and rubella (MMR) vaccine and varicella vaccine ([@R1],[@R3]). The recommendations for the timing of administration of GamaSTAN S/D with live-virus vaccines has not changed ([@R1],[@R3]). The Advisory Committee on Immunization Practices (ACIP) recommends that MMR and varicella vaccines should be administered at least 2 weeks before or at least 3 months after the administration of IG preparations ([@R1]). If an IG preparation must be administered less than 2 weeks after the administration of MMR or varicella vaccine, the patient should be revaccinated no sooner than 3 months after receipt of the IG preparation.

The absolute lower limit of anti-HAV IgG required to prevent HAV infection has not been defined; however, 10 mIU/mL is considered to be the minimum protective level for HAV prophylaxis ([@R1],[@R4]). The minimum anti-HAV IgG potency specified by the European Pharmacopoeia for intramuscular IG preparations indicated for HAV prophylaxis is \>100 IU/mL ([@R5]). A recent study showed that only two of nine tested lots of commercially available IG preparations manufactured in the United States, Europe, and Asia had anti-HAV IgG potency of 100 IU/mL ([@R6]). In addition, anti-HAV IgG decay models indicate that only five of nine lots of IG dosed at 0.02 mL/kg achieved postabsorption plasma anti-HAV IgG levels above the minimum protective level of 10 mIU/mL ([@R6]). The decay model also showed that none of the tested IG lots maintained the proposed minimal protective anti-HAV IgG level of 10 mIU/mL for 3 months ([@R6]).

Indications for the use of IG are based on ACIP recommendations published in 2007 for prevention of hepatitis A infection after exposure to HAV and in international travelers ([@R7]).

Preexposure Prophylaxis for International Travel
================================================

Hepatitis A vaccine at the age-appropriate dose is preferred to IG. For travel that will begin in ≤2 weeks to countries with high or intermediate hepatitis A endemicity, older adults, immunocompromised persons, and persons with chronic liver disease or other chronic medical conditions may receive IG simultaneously with hepatitis A vaccine at a separate anatomic injection site. Travelers who elect not to receive hepatitis A vaccine, who are aged \<12 months, or who are allergic to a component of hepatitis A vaccine should receive a single dose of IG before travel ([@R7]).

Postexposure Prophylaxis
========================

IG should be used for children aged \<12 months, immunocompromised persons, persons who have chronic liver disease, and persons for whom vaccine is contraindicated. IG is also preferred over hepatitis A vaccine for persons aged \>40 years; however, vaccine may be used if IG cannot be obtained ([@R7]).
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